A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
Times cited: 6
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
New England Journal of Medicine.
Times cited: 495